Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACTICLATE vs INCRELEX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inhibits P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), thereby increasing intestinal absorption and decreasing clearance of substrates; also inhibits CYP3A4 isoenzymes, reducing metabolism of CYP3A4 substrates.
Insulin-like growth factor 1 receptor agonist; promotes linear growth by stimulating chondrocyte proliferation at epiphyseal plates and exerts anabolic effects on muscle, bone, and other tissues.
Adjuvant therapy to antibiotics for treatment of refractory infections caused by multidrug-resistant organisms,Off-label: Treatment of hyperuricemia in gout (as a urate-lowering agent when combined with allopurinol),Investigationally: Reversal of P-gp-mediated resistance in certain malignancies
Treatment of growth failure in children with severe primary IGF-1 deficiency (primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH
100 mg orally twice daily (12 hours apart) on an empty stomach (1 hour before or 2 hours after meals). Avoid milk, antacids, iron, calcium, magnesium, and zinc within 2 hours of administration.
Intravenous bolus of 0.1 mg/kg given over 1 minute, followed by continuous intravenous infusion of 0.6 mg/kg/min for 30 minutes. Alternatively, a single intravenous bolus dose of 0.3 mg/kg.
Terminal elimination half-life is approximately 18-22 hours in patients with normal renal function; prolonged to 30-50 hours in moderate renal impairment (Cr Cl 30-50 m L/min).
Terminal elimination half-life is approximately 8-10 hours in adults; clinically, steady-state is achieved within 2-3 days.
Primarily hepatic via CYP3A4 and CYP2D6; also undergoes glucuronidation and renal excretion.
Primarily metabolized by proteolysis into smaller peptides and amino acids; not significantly metabolized by CYP enzymes.
Renal excretion of unchanged drug accounts for approximately 60% of the dose; fecal elimination via biliary secretion contributes about 30%; minor metabolism (<10%) produces inactive metabolites.
Renal: ~95% of absorbed dose as unchanged drug and metabolites; fecal: <5%.
Approximately 75-80% bound primarily to serum albumin and to a lesser extent to alpha-1-acid glycoprotein.
Approximately 90% bound to insulin-like growth factor binding proteins (IGFBPs).
Volume of distribution is 1.5-2.5 L/kg, indicating extensive tissue distribution; penetrates well into lung, skin, and soft tissues.
Vd ~0.3-0.5 L/kg, indicating distribution primarily into extracellular fluid.
Oral bioavailability is approximately 95% with minimal first-pass metabolism; food reduces absorption by 20-30%.
Subcutaneous: 80-100% (high bioavailability).
e GFR 30-60 m L/min/1.73m²: No adjustment needed; e GFR <30 m L/min: Avoid use (contraindicated due to tetracycline accumulation).
No specific dose adjustment recommended for renal impairment; use with caution in patients with severe renal impairment (e GFR < 30 m L/min/1.73 m²) due to limited data.
Child-Pugh Class A or B: No adjustment; Child-Pugh Class C: Avoid use (insufficient data, potential hepatotoxicity).
No specific dose adjustment recommended for hepatic impairment; use with caution in patients with Child-Pugh class C cirrhosis due to potential risk of hypoglycemia.
Weight ≥45 kg and age ≥12 years: 100 mg every 12 hours for 10 days. Weight <45 kg or age <12 years: Not recommended (risk of permanent tooth discoloration and bone growth inhibition).
Not approved for use in pediatric patients. Safety and efficacy in children have not been established.
Use with caution due to increased risk of intracranial hypertension and photosensitivity. Consider renal function; no specific dose adjustment beyond renal dosing.
No specific dose adjustment recommended; elderly patients may be more sensitive to hypoglycemic effects; monitor blood glucose closely.
None.
Increased risk of neoplasms; do not use in patients with active or suspected malignancy. Monitor for progression of pre-existing nevi.
May cause significant drug interactions due to inhibition of P-gp, BCRP, and CYP3A4; monitor for increased toxicity of coadministered drugs (e.g., digoxin, methotrexate, anticancer agents). Use with caution in patients with hepatic impairment.
Risk of malignancy (including intracranial tumors),Lymphoproliferative disorders,Intracranial hypertension (pseudotumor cerebri),Slipped capital femoral epiphysis,Progression of scoliosis,Pancreatitis,Hypoglycemia (especially with fasting or missed meals),Fluid retention (edema, pericardial effusion),Hypersensitivity reactions including anaphylaxis,Thymic hypertrophy
Hypersensitivity to active ingredient; concurrent use with narrow therapeutic index drugs that are P-gp or CYP3A4 substrates (e.g., digoxin, colchicine, cyclosporine) unless benefit outweighs risk.
Active or suspected malignancy (including intracranial tumors),Closed epiphyses (skeletal maturity),Acute critical illness (due to increased mortality with ICU use),Hypersensitivity to mecasermin or any component
Dairy products (milk, yogurt, cheese), calcium-fortified foods, and high-calcium meals reduce doxycycline absorption. Take doxycycline at least 1-2 hours before or after consuming these foods. Avoid concurrent use with antacids, iron supplements, bismuth subsalicylate, and magnesium-containing laxatives. Alcohol is not known to interact but may increase gastrointestinal irritation.
Must be administered within 20 minutes of a meal or snack containing carbohydrates to reduce risk of hypoglycemia. Avoid fasting or skipping meals. Grapefruit/grapefruit juice may alter CYP3A4 metabolism; avoid concurrent use. Alcohol can increase hypoglycemia risk; limit or avoid.
FDA Pregnancy Category D. Tetracyclines, including doxycycline (active ingredient in ACTICLATE), can cause fetal harm when administered to a pregnant woman. Use during tooth development (second and third trimesters) may cause permanent discoloration of teeth (yellow-gray-brown) and enamel hypoplasia. Use during skeletal development may cause reversible inhibition of bone growth. Avoid during pregnancy; alternative therapy should be considered.
INCRELEX (mecasermin) is an IGF-1 analog. In animal studies, there is no evidence of teratogenicity; however, data in pregnant women are insufficient. First trimester: No known malformation risk. Second/third trimesters: Fetal overgrowth (macrosomia) may occur if maternal IGF-1 levels are elevated. Caution advised.
Doxycycline is excreted in human milk at low concentrations. The milk-to-plasma ratio is approximately 0.6-0.9. Theoretical risk of dental discoloration and bone growth inhibition in nursing infants exists due to cumulative effects, although absorption by the infant is limited. Caution is advised; consider temporary discontinuation of breastfeeding during treatment or use alternative agent.
Excretion into human milk unknown; molecular weight (7.5 k Da) suggests minimal transfer. M/P ratio not established. Caution recommended; alternative feeding may be considered until more data available.
Doxycycline is contraindicated in pregnancy; no dose adjustment is applicable. If inadvertent exposure occurs in first trimester, no dose adjustment needed, but drug should be discontinued. No pharmacokinetic data suggesting need for dose adjustment if used for life-threatening conditions (e.g., anthrax), but risk-benefit must be carefully assessed.
No established dose adjustments. Physiologic changes in pregnancy (increased renal clearance, plasma volume) may reduce drug levels; however, safety and efficacy data are lacking. Use only if clearly needed with careful monitoring.
ACTICLATE (doxycycline hyclate) is a tetracycline antibiotic. Avoid concomitant use with antacids, dairy products, or iron supplements as they chelate doxycycline, reducing absorption. Administer with a full glass of water and avoid lying down for 30 minutes to reduce esophageal irritation. Photosensitivity is common; advise sun avoidance and sunscreen use. Do not use in children <8 years or during pregnancy/lactation due to tooth discoloration and bone growth inhibition. Monitor for pseudomembranous colitis and superinfection.
INCRELEX (mecasermin) is recombinant human insulin-like growth factor-1 (IGF-1) used for growth failure in severe primary IGF-1 deficiency. Monitor blood glucose closely due to risk of hypoglycemia; administer within 20 minutes of a meal or snack. Do not use in patients with closed epiphyses, active malignancy, or history of malignancy. Can cause intracranial hypertension (pseudotumor cerebri); monitor for headache, visual disturbances. Injection site reactions common.
Take doxycycline exactly as prescribed. Do not skip doses or stop early even if you feel better.,Take with a full glass of water. Avoid lying down for at least 30 minutes after taking to prevent esophageal irritation.,Avoid taking with milk, yogurt, cheese, or calcium-fortified foods. Also avoid antacids, iron, and bismuth subsalicylate within 2 hours of doxycycline.,Use sunscreen and protective clothing; doxycycline increases sensitivity to sunlight and can cause severe sunburn.,If you miss a dose, take it as soon as you remember unless it is near the time of the next dose. Do not double the dose.,Report persistent diarrhea, severe headache, vision changes, or allergic reactions (rash, swelling) to your healthcare provider immediately.
Do not use INCRELEX if you have cancer or a history of cancer.,Take exactly as prescribed; inject within 20 minutes after a meal or snack to prevent low blood sugar.,Do not inject into the same site repeatedly; rotate injection sites.,Watch for signs of low blood sugar (shakiness, sweating, confusion) and have fast-acting sugar (e.g., juice, glucose tablets) available.,Report severe headache, vision changes, or nausea immediately (possible increased pressure in the skull).,Inform all healthcare providers you are using this medication.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACTICLATE vs INCRELEX, answered by our medical review team.
ACTICLATE is a Tetracycline Antibiotic that works by Inhibits P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), thereby increasing intestinal absorption and decreasing clearance of substrates; also inhibits CYP3A4 isoenzymes, reducing metabolism of CYP3A4 substrates.. INCRELEX is a Growth Factor that works by Insulin-like growth factor 1 receptor agonist; promotes linear growth by stimulating chondrocyte proliferation at epiphyseal plates and exerts anabolic effects on muscle, bone, and other tissues.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACTICLATE and INCRELEX depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACTICLATE is: 100 mg orally twice daily (12 hours apart) on an empty stomach (1 hour before or 2 hours after meals). Avoid milk, antacids, iron, calcium, magnesium, and zinc within 2 hours of administration.. The standard adult dose of INCRELEX is: Intravenous bolus of 0.1 mg/kg given over 1 minute, followed by continuous intravenous infusion of 0.6 mg/kg/min for 30 minutes. Alternatively, a single intravenous bolus dose of 0.3 mg/kg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACTICLATE and INCRELEX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACTICLATE is classified as Category C. FDA Pregnancy Category D. Tetracyclines, including doxycycline (active ingredient in ACTICLATE), can cause fetal harm when administered to a pregnant woman. Use during tooth develo. INCRELEX is classified as Category C. INCRELEX (mecasermin) is an IGF-1 analog. In animal studies, there is no evidence of teratogenicity; however, data in pregnant women are insufficient. First trimester: No known mal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.